Illinois

Showing 1-10 of 16 grants

Title	Institution	Researcher	Program	Duration	Total Award Amount
Programming Pancreatic Cell Replacement Therapeutics Using Cellgorithm Technology	Syntax Bio, Inc	Ryan Clarke	Cures	15-November-2025 to 14-November-2027	$856,250.00
Safety and efficacy assessment of Tegoprubart and calcineurin inhibitors- free immunosuppression therapy for pancreatic islet transplantation in patients with t1DM and chronic kidney disease.	The University of Chicago	Piotr Witkowski	Cures	01-September-2025 to 31-August-2029	$8,500,000.00
Dissecting HLA Mechanisms in T1D, SLE, and MS Through High-Throughput Self-Antigen Profiling	The University of Chicago	Aly Khan	Cures	01-September-2025 to 31-August-2026	$150,000.00
PLGA nanoparticle treatment-induced antigen-specific CD4+ regulatory T cell control of effector CD8+ T cell responses in a model of type 1 diabetes	Northwestern University	Stephen Miller	Cures	01-September-2025 to 31-August-2028	$659,990.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation	The University of Chicago	Piotr Witkowski	Cures	01-February-2025 to 31-January-2027	$1,500,000.00
Development of β-Cell Targeted Lipid Nanoparticle Therapeutics	The University of Chicago	Jacob Ryan Enriquez	Cures	01-March-2025 to 29-February-2028	$247,790.00
A hybrid effectiveness implementation trial of an intervention to reduce diabetes-specific emotional distress.	Ann & Robert H. Lurie Children’s Hospital of Chicago	Jill Weissberg-Benchell	Improving Lives	01-September-2024 to 31-August-2029	$1,936,551.00
A New Preparation of the Intact Eye for Measurements of Retinal Dysfunction in Acute Hyperglycemia and Early Diabetes	Northwestern University	Gregory Schwartz	Improving Lives	01-October-2023 to 30-September-2026	$406,927.40
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation	The University of Chicago	Piotr Witkowski	Cures	01-February-2024 to 31-January-2026	$250,000.00
Risk and Protective Factors for Optimal Health Outcomes in Children with Type 1 Diabetes (T1D) and their Parents	Ann & Robert H. Lurie Children’s Hospital of Chicago	Jillian Merrick	Transportfolio	01-September-2023 to 31-August-2025	$129,046.51